Exelixis Reports Strong Q3 2024 Earnings and Pipeline Expansion
Company Announcements

Exelixis Reports Strong Q3 2024 Earnings and Pipeline Expansion

Exelixis ( (EXEL) ) has realeased its Q3 earnings. Here is a breakdown of the information Exelixis presented to its investors.

Exelixis, Inc. is an innovative oncology company focusing on drug discovery and development to provide next-generation cancer treatments. The company’s third-quarter 2024 earnings report highlights a significant increase in total revenues to $539.5 million, driven by strong sales of its cabozantinib franchise and expanded collaborations. Notably, the company reported a favorable ruling in patent litigation and announced a new partnership with Merck, enhancing its pipeline with six phase 3 trials for zanzalintinib. Financially, Exelixis achieved a GAAP diluted EPS of $0.40 and non-GAAP diluted EPS of $0.47, alongside increased financial guidance for 2024. The company is confident in its growth trajectory, focusing on advancing its clinical pipeline and exploring new cancer treatment opportunities.

Related Articles
TheFlyExelixis director Poste sells 30,000 common shares
TheFlyExelixis general counsel Hessekiel sells 50,000 common shares
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App